LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-10.82%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$1.02B
AUM Growth
+$1.02B
(-11%)
Cap. Flow
+$84.4M
Cap. Flow
% of AUM
8.23%
Top 10 Holdings %
Top 10 Hldgs %
68.99%
Holding
83
New
24
Increased
8
Reduced
9
Closed
29
Top Buys
| 1 |
Design Therapeutics
DSGN
|
$81.7M |
| 2 |
Instil Bio
TIL
|
$46.3M |
| 3 |
Edgewise Therapeutics
EWTX
|
$34.3M |
| 4 |
Dyne Therapeutics
DYN
|
$24.8M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$23.9M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$44.2M |
| 2 |
Keros Therapeutics
KROS
|
$31.7M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$17.2M |
| 4 |
Avidity Biosciences
RNA
|
$17.1M |
| 5 |
Nkarta
NKTX
|
$13.9M |
Sector Composition
| 1 | Healthcare | 99.46% |
| 2 | Financials | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IGMS
76
DELISTED
IGM Biosciences
IGMS
| – | – |
-150,000
| Closed | -$13.2M |
|
77
Generation Bio
GBIO
$40.3M
| – | – |
-17,000
| Closed | -$482K |
|
78
EyePoint Pharmaceuticals
EYPT
$827M
| – | – |
-699,999
| Closed | -$4.61M |
|
79
ESSA Pharma
EPIX
$11.2M
| – | – |
-550,000
| Closed | -$6.56M |
|
80
Curis
CRIS
$21.5M
| – | – |
-1,200,000
| Closed | -$9.83M |
|
81
Black Diamond Therapeutics
BDTX
$164M
| – | – |
-123,465
| Closed | -$3.96M |
|
|
82
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-300,000
| Closed | -$17.2M |
|
83
AbCellera Biologics
ABCL
$1.19B
| – | – |
-300,000
| Closed | -$12.1M |
|